Cargando…

The Diagnostic and Prognostic Value of Plasma Galectin 3 in HFrEF Related to the Etiology of Heart Failure

Aim: The aim of present study is to evaluate the diagnostic and prognostic value of plasma galectin 3 (Gal-3) for HF originating from different causes. Methods: We investigated the plasma levels and expression of Gal-3 in cardiac tissues in two transgenic (TG) strains of mice with cardiomyocyte-rest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Qun, Zhang, Ruo-Chen, Chen, Shu-Ping, Li, Tao, Wang, Ya, Xue, Yan-Bo, Liu, Jing, Han, Xiu, Su, Yi-Dan, Bai, Ling, Du, Xiao-Jun, Ma, Ai-Qun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727364/ https://www.ncbi.nlm.nih.gov/pubmed/35004876 http://dx.doi.org/10.3389/fcvm.2021.748875

Ejemplares similares

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF)
por: Spannbauer, Andreas, et al.
Publicado: (2019)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

Chronic Kidney Disease Increases Risk of Incident HFrEF Following Percutaneous Coronary Intervention
por: Lai, Wenguang, et al.
Publicado: (2022)

The loss of left atrial contractile function predicts a worse outcome in HFrEF patients
por: Mandoli, Giulia Elena, et al.
Publicado: (2023)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation?
por: Wang, Wenyan, et al.
Publicado: (2023)

Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
por: Prausmüller, Suriya, et al.
Publicado: (2020)

Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Getting ahead of the game: in-hospital initiation of HFrEF therapies
por: Biegus, Jan, et al.
Publicado: (2022)

Neprilysin in HFrEF: Differential Regulation of Tissue Versus Circulating Neprilysin
por: Chen, Horng H., et al.
Publicado: (2020)

Mortality and Morbidity in HFrEF, HFmrEF, and HFpEF Patients with Diabetes in the Middle East
por: Al-Jarallah, Mohammed, et al.
Publicado: (2020)

Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs
por: Chen, Yei-Tsung, et al.
Publicado: (2019)

A horse of a different colour: distinct mechanisms of HFpEF and HFrEF
por: Louch, William E.
Publicado: (2020)

Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
por: Jun, Seungho, et al.
Publicado: (2019)

Association of Depression Symptoms and Biomarkers of Risk on Clinical Outcomes in HFrEF
por: Sherwood, Andrew, et al.
Publicado: (2023)

Corrigendum to: Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
Publicado: (2023)

Quality of life questionnaire predicts poor exercise capacity only in HFpEF and not in HFrEF
por: Ahmeti, Artan, et al.
Publicado: (2017)

Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
por: Kristensen, Søren L., et al.
Publicado: (2017)

Myocardial phenotypes and dysfunction in HFpEF and HFrEF assessed by echocardiography and cardiac magnetic resonance
por: Berlot, Bostjan, et al.
Publicado: (2019)

Disparate Clinical Characteristics and Prognosis of HFpEF versus HFrEF Phenotype of Diabetic Cardiomyopathy
por: Li, Zheng, et al.
Publicado: (2023)

A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
por: Reed, Brent N, et al.
Publicado: (2015)

Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF)
por: Benes, Jan, et al.
Publicado: (2022)

Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting
por: Naser, Nabil, et al.
Publicado: (2022)

The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
por: Docherty, Kieran F, et al.
Publicado: (2022)

Intrarenal Doppler ultrasonography in patients with HFrEF and acute decompensated heart failure undergoing recompensation
por: Wallbach, M., et al.
Publicado: (2023)

The Predictive Value of Eosinophil Indices for Major Cardiovascular Events in Patients with Acute Decompensated HFrEF
por: Vural, Aslı, et al.
Publicado: (2022)

Quantification of pulmonary edema in heart failure using MRI: invasive validation and evaluation in HFpEF and HFrEF patients
por: Thompson, Richard B, et al.
Publicado: (2016)

FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF
por: Benes, Jan, et al.
Publicado: (2023)

Right ventricular global dysfunction score: a new concept of right ventricular function assessment in patients with heart failure with reduced ejection fraction (HFrEF)
por: Benes, Jan, et al.
Publicado: (2023)

Amiodarone vs. metoprolol succinate in HFrEF complicated with persistent atrial fibrillation with rapid ventricular response: A prospective observational study
por: Liu, Yongrong, et al.
Publicado: (2023)

The vasculature in HFpEF vs HFrEF: differences in contractile protein expression produce distinct phenotypes
por: Lyle, Melissa A., et al.
Publicado: (2019)

Ubiquitin‐proteasome‐system and enzymes of energy metabolism in skeletal muscle of patients with HFpEF and HFrEF
por: Adams, Volker, et al.
Publicado: (2021)

Association of preexisting hypertension with the morality in patients with systolic heart failure in Taiwan: The TSOC-HFrEF registry
por: Meng, Fan-Chun, et al.
Publicado: (2018)

Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials
por: Dixit, Neal M., et al.
Publicado: (2023)

Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF
por: Simon, Judit, et al.
Publicado: (2019)

Sacubitril/valsartan in HFrEF – Should the aces up our sleeves be played earlier?
por: Boehmer, Andreas A., et al.
Publicado: (2019)

The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients
por: Liao, Chia‐Te, et al.
Publicado: (2021)

Echocardiographic Parameters as Predictors for the Efficiency of Resynchronization Therapy in Patients with Dilated Cardiomyopathy and HFrEF
por: Pescariu, Silvius-Alexandru, et al.
Publicado: (2021)

Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients
por: Campanile, Alfonso, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9gf1gn2dlmhfko2pkepjbol2ag